Reaction
Injection Site Hypoaesthesia reporting signals
As of the last recalculation, Injection Site Hypoaesthesia appears in 1,392 FAERS reports alongside 24 co-occurring drug terms. The strongest observed disproportionality signal is EPINEPHRINE (PRR 19.1).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Epinephrine | 79 | 19.1 | 19.1 |
| Botulinum Toxin Type A | 14 | 17.0 | 17.0 |
| Alirocumab | 25 | 15.2 | 15.2 |
| Onabotulinumtoxina | 55 | 11.1 | 11.1 |
| Asfotase Alfa | 7 | 10.5 | 10.5 |
| Glatiramer Acetate | 38 | 9.7 | 9.8 |
| Naltrexone | 19 | 9.3 | 9.3 |
| Pegvaliase-Pqpz | 5 | 9.1 | 9.1 |
| Ofatumumab | 19 | 8.7 | 8.7 |
| Fremanezumab-Vfrm | 6 | 7.8 | 7.8 |
| Tirzepatide | 79 | 7.7 | 7.7 |
| Lanreotide Acetate | 4 | 7.6 | 7.7 |
| Cabotegravir | 4 | 7.4 | 7.4 |
| Omalizumab | 41 | 7.4 | 7.4 |
| Erenumab-Aooe | 22 | 6.1 | 6.1 |
| Dulaglutide | 34 | 5.9 | 5.9 |
| Galcanezumab-Gnlm | 12 | 5.7 | 5.7 |
| Evolocumab | 60 | 5.7 | 5.7 |
| Peginterferon Beta-1A | 5 | 5.7 | 5.7 |
| Romosozumab-Aqqg | 5 | 5.5 | 5.5 |
| Dupilumab | 106 | 3.5 | 3.5 |
| Paliperidone Palmitate | 7 | 3.3 | 3.3 |
| Ixekizumab | 8 | 3.2 | 3.2 |
| Abaloparatide | 6 | 3.1 | 3.1 |